Pharmaceuticals
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved ...
2025-03-10 19:22
2754
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) inJapan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). H. Lundbeck A/S (Lundbeck) a...
2025-03-10 16:57
2504
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
* The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials. * In preclinical studies, EVM16 demonstrated...
2025-03-06 16:30
3048
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561 for the treatment of newly diagnosed glioblastoma ...
2025-03-05 22:45
2319
CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland
* CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities acrossEurope and the US. * In Switzerland, CordenPharma will invest >€500m to construct a greenfield site for small to lar...
2025-03-05 13:30
3053
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for multiple ind...
2025-03-05 13:00
2925
GHIT-backed Innovation Achieves Landmark: New Treatment Option for Schistosomiasis Reaches Preschool-Aged Children
TOKYO, March 5, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is today announcing a significant milestone: the first administration of arpraziquantel to preschool-aged children inUganda, in an implementation science setting. This new pediatric treatment for schistosomi...
2025-03-05 09:00
2584
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")
REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation inChina for the treatment of fat reduction in the submental area. Submental fat...
2025-03-04 09:00
2278
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology. In ...
2025-03-04 05:58
2884
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
* Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience * Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside o...
2025-03-03 22:00
3927
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
* First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model * Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VA...
2025-03-03 21:00
2087
Sole Pharma - Launches in the Philippines to Meet Rising Demand for High-Quality Supplements
MANILA, Philippines, March 3, 2025 /PRNewswire/ -- In response to the growing demand for high-quality health supplements in the Philippines, Sole Pharma, as one of the leading Europeanpharmaceutical manufacturer, announces its expansion into the Southeast Asian market. Products are available onli...
2025-03-03 08:55
2877
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-03-03 08:00
5662
Hospital Kuala Lumpur & Rare Disease Patient Organizations Nationwide Celebrate Rare Disease Day 2025
KUALA LUMPUR, Malaysia, March 1, 2025 /PRNewswire/ -- For the first time, Hospital Kuala Lumpur (HKL) is proudly hosting the annual Rare Disease Day 2025 celebration to raise awareness and advocate for individuals affected by rare diseases inMalaysia. This milestone event is organized by the Depa...
2025-03-01 22:30
5242
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor...
2025-02-28 14:28
5426
Nezha Craze Sweeps the City Wai Yuen Tong Proudly Sponsors Broadcast of "Nezha: The Demon Child Comes into the World" on Jade Channel
HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Hong Kong's traditional Chinese medicine pioneer Wai Yuen Tong (0897.HK) announced its proud sponsorship of the TVB Jade Channel's broadcast of the film " Nezha: The Demon Child Comes into the World " (Nezha 1) onFebruary 28 at 8 PM. This film will provid...
2025-02-27 20:09
4465
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection byJapan's Pharmaceuticals and Medical Devices Agency (PMDA) for it...
2025-02-27 16:30
3927
Clarivate Report Explores Opportunities for Innovation and Market Expansion in Latin America
New insights from Clarivate examine strategic partnerships, API production, and innovation in the region LONDON, Feb. 27, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, has released a new white paper, How is Latin America Growing?, sheddi...
2025-02-27 16:00
2410
Alpro Foundation & Universiti Teknologi MARA: Addressing Malaysia's Pharmaceutical Waste
KUALA LUMPUR, Malaysia, Feb. 27, 2025 /PRNewswire/ -- Malaysia is facing a growing environmental and public health threat due to improper disposal of pharmaceutical waste. Research indicates that 67% of Malaysians discard expired medications incorrectly—either by flushing them down the toilet or ...
2025-02-27 15:19
3207
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 bip...
2025-02-27 14:06
4800
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24